PARIS, IDF, France - Carthera®, a clinical-stage medtech company specializing in the development of revolutionary ultrasound-based medical devices for the treatment of severe brain disorders, announced today the successful completion of its Series B funding round, raising a total of $41,077,875. The investment was led by Supernova Invest and Panakes Partners, two prominent venture capital firms in the healthcare sector.

Carthera® aims to transform the field of brain disease treatment by leveraging its proprietary medical device, SonoCloud®. SonoCloud® is a groundbreaking technology that utilizes ultrasound to temporarily enhance the permeability of blood vessels in the brain. This breakthrough innovation holds the potential to unlock and harness the therapeutic efficacy of both new and existing therapies, significantly improving the treatment outcomes for a wide range of brain disorders.

Frédéric Sottilini, Founder of Carthera®, expressed his enthusiasm for the recent funding success, stating, "We are delighted to have the support of Supernova Invest and Panakes Partners in this funding round. Their confidence in Carthera's vision and technology underscores the potential of our ultrasound-based approach to revolutionize the treatment landscape for severe brain disorders."